Morgan Stanley Reiterates a “Equal weight” Rating on Hikma Pharmaceuticals PLC (LON:HIK) and GBX 1050.00 Target; Ocwen Financial (OCN) Had 1 Bulls

Equities researchers at Morgan Stanley have GBX 1050.00 target price on Hikma Pharmaceuticals PLC (LON:HIK). Morgan Stanley’s target price gives a potential downside of -4.24% from the company’s last close price. The rating was disclosed to clients in a research report on Thursday morning.

Among 10 analysts covering Ocwen Financial (NYSE:OCN), 1 have Buy rating, 2 Sell and 7 Hold. Therefore 10% are positive. Ocwen Financial had 25 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Ocwen Financial Corporation (NYSE:OCN) earned “Buy” rating by Zacks on Thursday, August 6. As per Monday, April 24, the company rating was upgraded by Compass Point. The company was maintained on Thursday, April 28 by Compass Point. On Wednesday, September 2 the stock rating was upgraded by Vetr to “Strong-Buy”. Compass Point maintained the stock with “Sell” rating in Tuesday, August 4 report. The rating was maintained by Piper Jaffray on Monday, July 24 with “Hold”. Keefe Bruyette & Woods maintained the shares of OCN in report on Friday, October 6 with “Hold” rating. The rating was maintained by Compass Point with “Neutral” on Thursday, December 3. As per Friday, July 31, the company rating was downgraded by Sterne Agee CRT. The firm has “Neutral” rating given on Thursday, January 12 by Compass Point. See Ocwen Financial Corporation (NYSE:OCN) latest ratings:

28/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $3.25 Maintain
06/10/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $3.0 Maintain

Hikma Pharmaceuticals PLC develops, makes, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. The company has market cap of 2.64 billion GBP. It operates through three divisions: Branded, Injectables, and Generic. It has a 15.89 P/E ratio. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system , gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

The stock increased 17.60% or GBX 167.5 during the last trading session, reaching GBX 1096.5. About 2.03M shares traded or 221.75% up from the average. Hikma Pharmaceuticals PLC (LON:HIK) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 15 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 6 have Buy rating, 3 Sell and 6 Hold. Therefore 40% are positive. Hikma Pharmaceuticals PLC has GBX 3400 highest and GBX 800 lowest target. GBX 1403.14’s average target is 27.97% above currents GBX 1096.5 stock price. Hikma Pharmaceuticals PLC had 169 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Peel Hunt with “Hold” on Tuesday, October 31. The company was maintained on Thursday, November 9 by Jefferies. J.P. Morgan maintained the stock with “Overweight” rating in Wednesday, January 27 report. HSBC maintained the stock with “Reduce” rating in Friday, May 5 report. The firm earned “Buy” rating on Friday, June 24 by Stifel Nicolaus. The firm earned “Neutral” rating on Monday, May 22 by JP Morgan. JP Morgan maintained Hikma Pharmaceuticals PLC (LON:HIK) on Tuesday, August 16 with “Overweight” rating. Barclays Capital maintained the stock with “Overweight” rating in Friday, September 9 report. The stock of Hikma Pharmaceuticals PLC (LON:HIK) earned “Overweight” rating by Morgan Stanley on Tuesday, November 15. The rating was maintained by Peel Hunt with “Buy” on Friday, February 24.

Ocwen Financial Corporation, a financial services holding company, engages in the servicing and origination of mortgage loans in the United States. The company has market cap of $574.11 million. The Company’s Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset management services to owners of mortgage loans and foreclosed real estate. It currently has negative earnings. This segmentÂ’s residential servicing portfolio includes conventional, government insured, and non-agency loans.

Investors sentiment increased to 1.2 in 2017 Q3. Its up 0.36, from 0.84 in 2017Q2. It is positive, as 23 investors sold Ocwen Financial Corporation shares while 27 reduced holdings. 15 funds opened positions while 27 raised stakes. 57.15 million shares or 5.73% less from 60.63 million shares in 2017Q2 were reported. Northern Tru reported 2.21M shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 2,811 shares. Financial Bank Of America De holds 0% in Ocwen Financial Corporation (NYSE:OCN) or 41,955 shares. State Board Of Administration Of Florida Retirement Sys has 84,941 shares. Next Fincl Grp Inc invested 0% of its portfolio in Ocwen Financial Corporation (NYSE:OCN). Geode Capital Management Ltd Limited Liability Company has invested 0% in Ocwen Financial Corporation (NYSE:OCN). Millennium Mgmt Ltd Liability Corp stated it has 0% of its portfolio in Ocwen Financial Corporation (NYSE:OCN). Ubs Asset Mgmt Americas Inc reported 34,899 shares stake. Brown Brothers Harriman And Com has invested 0% in Ocwen Financial Corporation (NYSE:OCN). Sg Americas Securities Limited Liability Company invested 0% in Ocwen Financial Corporation (NYSE:OCN). Natixis reported 12,846 shares. Raymond James owns 128,000 shares. Manufacturers Life Ins Company The reported 0% of its portfolio in Ocwen Financial Corporation (NYSE:OCN). Swiss Commercial Bank has invested 0% in Ocwen Financial Corporation (NYSE:OCN). Berson & Corrado Advisors Limited Co has invested 0.13% of its portfolio in Ocwen Financial Corporation (NYSE:OCN).